Anemia, a common hematological disorder, presents a diagnostic challenge due to its multifactorial etiology. This article aims to simplify the diagnostic approach for healthcare professionals.
Anemia is broadly classified based on the Mean Corpuscular Volume (MCV). Microcytic anemia is often due to iron deficiency or thalassemia. Normocytic anemia might indicate chronic disease, while macrocytic anemia could suggest vitamin B12 or folate deficiency.
Initial evaluation includes a complete blood count and reticulocyte count. If MCV is low, iron studies or hemoglobin electrophoresis can be undertaken. For normal MCV, serum creatinine and erythrocyte sedimentation rate tests are beneficial. In case of high MCV, serum B12 and folate levels should be assessed.
Unexplained or severe anemia may warrant bone marrow examination. Genetic testing is useful in suspected hereditary anemias. Other advanced investigations include endoscopy, colonoscopy, or computed tomography scans to identify potential sources of blood loss.
Diagnosing anemia requires a systematic approach, starting with an etiological classification followed by targeted investigations. Understanding the complexity of anemia is essential for effective patient management and treatment.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation